Abstract:The conversion yield is enhanced through the discovery of an intramolecular π‐π interaction between the target molecule and a photoremovable protective group, which is achieved by chemical modification of the prodrug. A triplet–triplet annihilation‐mediated photocleavage approach is developed to prevent tumor vascular growth for synergistic tumor treatment in conjunction with a red‐light photosensitizer. Highly spatiotemporal‐resolved photomodulation demonstrates promise for investigating key biological events in vivo and in vitro, such as cell signaling pathways, neuromodulation, and tumor treatment without side effects. However, enhancing the performance of photomodulation tools remains challenging due to the limitations of the physicochemical properties of the photoactive molecules. Here, a compact, stable intramolecular π‐π stacking conformation forming between the target molecule (naproxen) and the perylene‐based photoremovable protecting group is discovered to confine the motion of the photolabile bond and then enhance the photocleavage quantum yield. In conjunction with a red‐absorbing photosensitizer, the photocleavage wavelength is extended to the red region via triplet–triplet annihilation. In particular, the triplet lifetime of the prodrug can be extended via the linked steric hindrance to improve the conversion yield via TTA. Using the new photomodulation tool, it is precisely photoreleased cyclooxygenase‐2 inhibitors for tumor vascular growth suppression in vivo. In combination with cisplatin, over 90% efficient inhibition of malignant breast tumors is observed via the synergistic tumor treatment strategy. These findings provide a new concept for the rational design of efficient photocleavage and have implications for photomodulating cell signaling pathways in tumor therapy, as well as laying a solid foundation for the development of phototherapeutic approaches.

A Novel O-Nitrobenzyl-Based Photocleavable Antitumor Prodrug with the Capability of Releasing 5-Fluorourail

Biocompatible drug delivery system for photo-triggered controlled release of 5-Fluorouracil.

Photo and Redox Dual Responsive Reversibly Cross-Linked Nanocarrier for Efficient Tumor-Targeted Drug Delivery

Design, Synthesis, and Evaluation of Doxifluridine Derivatives as Nitroreductase-Responsive Anticancer Prodrugs

A Novel Anticancer Theranostic Pro-Prodrug Based on Hypoxia and Photo Sequential Control.

Synthesis of Novel Spin-Labeled Derivatives of 5-FU As Potential Antineoplastic Agents

Photoresponsive Prodrug‐dye Nanoassembly for In‐situ Monitorable Cancer Therapy

Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2 '-Deoxyuridine for the Treatment of Hepatocellular Carcinoma

Compact Molecular Conformation of Prodrugs Enhances Photocleaving Performance for Tumor Vascular Growth Inhibition

A Guanosine-Derived Antitumor Supramolecular Prodrug

In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug

Photocatalytic Nitroaromatic Prodrug Activation by Functionalized Gold Nanoclusters

Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

An acid-activatable fluorouracil prodrug for colorectal cancer synergistic therapy

Unprecedented Synthesis, in Vitro and in Vivo Anti-Cancer Evaluation of Novel Triazolonaphthalimide Derivatives.

Mitochondrial-targeted Prodrug Cancer Therapy Using a Rhodamine B Labeled Fluorinated Docetaxel

Bioinspired Nano‐Prodrug with Enhanced Tumor Targeting and Increased Therapeutic Efficiency

Therapeutic applications of responsive organic photocatalytic polymers, enabling in situ drug activation

Tumor-overexpressed enzyme responsive amphiphiles small molecular self-assembly nano-prodrug for the chemo-phototherapy against non-small-cell lung cancer

Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents

Reactive Oxygen Species Activatable Heterodimeric Prodrug as Tumor-Selective Nanotheranostics